Portugal Cannabis Market Decline: Analyzing the Impact of Licensing Reductions

By João L. Carapinha

May 15, 2026

Portugal cannabis market decline

The Portugal cannabis market decline has accelerated sharply since January 2026. Official Infarmed IP lists show that more than 30 percent of entities authorised for medicinal cannabis activities in Portugal have been suspended or permanently removed, producing a measurable contraction across cultivation, import, export, manufacturing, and wholesale trade. The sharpest percentage decline occurred in cultivation, which lost approximately 36 percent of listed operators between 3 January and 8 May, while export and import categories each fell by roughly 27 percent and 25 percent. New entries, such as Preze, Lda., partially offset these exits, yet the net result remains fewer licensed companies in every category than existed at the start of the year.

Licence Losses Mount

Data extracted directly from Infarmed’s lists reveal that fifteen cultivation licences, fifteen export licences, and fourteen import licences were withdrawn during the observation window, with only two new operators added to the import and export lists. The companies removed from cultivation included Ahara SA, Tilray Portugal, and several smaller entities such as Sinnabis and Canascer; parallel exits affected manufacturing and wholesale trade, although at lower absolute numbers. An internal Infarmed source confirmed that not all absences stem from routine annual renewals, yet the regulator has not disclosed how many cases involve non-compliance, revocation, or simple expiry.

Renewal Rules Drive Exits

Portuguese legislation requires annual renewal of cultivation, manufacturing, wholesale, import, and export authorisations, with applications due at least sixty days before expiry; failure to complete the process results in automatic removal from the published lists. Revocation or suspension for up to six months may also occur when technical or compliance failures are identified. Because the lists are updated continuously, absence from the register prevents an operator from requesting import or export certificates, thereby halting those activities regardless of whether the underlying licence has formally lapsed or is merely under administrative review.

Investor Confidence Wanes

The Portugal cannabis market decline raises questions about Portugal’s continued role as a European production and export hub, particularly given that current licence counts in cultivation, import, and export have fallen below the levels recorded in December 2023. Operators report difficulties communicating with the regulator and navigating non-intuitive platforms, while the absence of a distinct “under renewal” category leaves external observers unable to distinguish temporary administrative gaps from more substantive compliance issues. These uncertainties directly affect the predictability of supply chains and the ability of remaining firms to plan long-term investment and capacity decisions within the medicinal cannabis sector.

Reference url

Recent Posts

Cemiplimab Cervical Cancer Access
Cemiplimab Cervical Cancer Access Navigating Treatment and Value

By João L. Carapinha

June 24, 2026

Cemiplimab Cervical Cancer Access has been endorsed by NICE for adults with recurrent or metastatic cervical cancer that has progressed after platinum-based chemotherapy, provided patients have not previously received immunotherapy. The final draft guidance confirms that this PD-1 inhibitor deliv...
pharmaceutical innovation ROI
Shifting Perspectives on Pharmaceutical Innovation ROI as Socioeconomic Investment

By João L. Carapinha

June 24, 2026

Pharmaceutical innovation ROI is shifting from a narrow budget metric to a powerful indicator of societal return. Between 2014 and 2024, a 3.1-year rise in utilization-weighted mean drug vintage across 29 European countries prevented 1.83 million years of life lost before age 85 and saved 20.9 mi...
CAR T-Cell Therapy
Pioneering CAR T-Cell Therapy for Advanced Gastric Cancer

By João L. Carapinha

June 24, 2026

CAR T-Cell Therapy has reached a historic milestone with the approval of satri-cel, the world’s first authorized CAR T treatment for any solid tumor. The therapy targets Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma that has progressed after at l...